Susana Ramalho

Susana Ramalho

Auto-generated profile, based on publicly available information

Susana Ramalho

Grupo Brasileiro de Estudo em Câncer de Mama (GBECAM), São Paulo, Brazil

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
LSLuis Felipe Sallum
Luis Felipe Sallum
LALiliana Andrade
Liliana Andrade
SRSusana Ramalho
Susana Ramalho
AFAmanda Canato Ferracini
Amanda Canato Ferracini
RNRodrigo de Andrade Natal
Rodrigo de Andrade Natal
SDSophie Derchain
Sophie Derchain
WT1, p53 and p16 expression in the diagnosis of low- and high-grade serous ovarian carcinomas and their relation to prognosis WT1, p53 and p16 expression in the diagnosis of low- and high-grade serous ovarian carcinomas and their relation to prognosis

15 October 2022 in Cancers
Verified
Journal Article
Open access
PDF file
Marcella Regina CardosoMarcella Regina Cardoso
Marcella Regina Cardoso
ÁRÁlex Rosini
Álex Rosini
MTMaria Cecília Ramiro Talarico
Maria Cecília Ramiro Talarico
PSPedro Henrique Godoy Sanches
Pedro Henrique Godoy Sanches
MSMauricio Luis Sforça
Mauricio Luis Sforça
SDSophie Françoise Mauricette Derchain
Sophie Françoise Mauricette Derchain
Neoadjuvant chemotherapy (NACT) is offered to patients with operable or inoperable breast cancer (BC) to downstage the disease. Clinical responses to NACT may vary depending on a few known clinical and biological features, but the diversity of responses to NACT is not fully understood. In this study, 80 women had their metabolite profiles of pre-treatment sera analyzed for potential NACT response biomarker candidates in combination with immunohistochemical parameters using Nuclear Magnetic Resonance (NMR). Sixty-four percent of the patients were resistant to chemotherapy. NMR, hormonal receptors (HR), human epidermal growth factor receptor 2 (HER2), and the nuclear protein Ki67 were combined through machine learning (ML) to predict the response to NACT. Metabolites such as leucine, formate, valine, and proline, along with hormone receptor status, were discriminants of response to NACT. The glyoxylate and dicarboxylate metabolism was found to be involved in the resistance to NACT. We obtained an accuracy in excess of 80% for the prediction of response to NACT combining metabolomic and tumor profile data. Our results suggest that NMR data can substantially enhance the prediction of response to NACT when used in combination with already known response prediction factors.

3 April 2020 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
TRTomas Reinert
Tomas Reinert
SRSusana Ramalho
Susana Ramalho
VVVivian Castro Antunes de Vasconcelos
Vivian Castro Antunes de Vasconcelos
LSLeonardo Roberto Silva
Leonardo Roberto Silva
ASAna Elisa Ribeiro da Silva
Ana Elisa Ribeiro da Silva
MGMarcia Silveira Graudenz
Marcia Silveira Graudenz
Introduction: Mutations in the ESR1 gene (ESR1m) are important mechanisms of resistance to endocrine therapy in estrogen receptor–positive (ER+) metastatic breast cancer and have been studied as a potential therapeutic target, as well as a predictive and prognostic biomarker. Nonetheless, the role of ESR1m as a possible mechanism of primary endocrine resistance, as well as whether it also occurs in tumors that are resistant to ET administered in early-stage disease as (neo)adjuvant, has not been adequately studied. In this study, we evaluated the prevalence of ESR1m in tumor samples from patients with ER+ breast cancer resistant to neoadjuvant aromatase inhibitor therapy. Methods: We followed a prospective cohort of patients with ER+ HER2– stages II and III breast cancer treated with neoadjuvant endocrine therapy (NET). Tumor samples from patients with a pattern of primary endocrine resistance [defined as a Preoperative Endocrine Prognostic Index (PEPI) score of ≥4] were identified and analyzed for the presence of ESR1m. Results: One hundred twenty-seven patients were included in the cohort, of which 100 (79%) had completed NET and underwent surgery. Among these patients, the PEPI score ranged from 0 to 3 in 70% (70/100), whereas 30% (30/100) had a PEPI score of 4 or more. Twenty-three of these patients were included in the analysis. ESR1 mutations were not identified in any of the 23 patients with early-stage ER+ breast cancer resistant to NET. Discussion: Growing evidence supports the notion that there are different mechanisms for primary and secondary endocrine resistance. Our study suggests that ESR1 mutations do not evolve rapidly and do not represent a common mechanism of primary endocrine resistance in the neoadjuvant setting. Therefore, ESR1m should be considered a mechanism of acquired endocrine resistance in the context of advanced disease. Further research should be conducted to identify factors associated with intrinsic resistance to ET.

1 January 2019 in Tumor Biology
Verified
Journal Article
Open access
PDF file
SRSusana Ramalho
Susana Ramalho
LALiliana AL De Angelo Andrade
Liliana AL De Angelo Andrade
CFCássio Cardoso Filho
Cássio Cardoso Filho
RNRodrigo de Andrade Natal
Rodrigo de Andrade Natal
MPMarina Pavanello
Marina Pavanello
SDSophie Derchain
Sophie Derchain
The objective of this study is to evaluate the relationship between discoidin domain receptor 2 (DDR2) and miR-182 expression with response to platinum-based chemotherapy and survival in women with high-grade serous ovarian cancer (HGSOC). We evaluated 78 women with HGSOC stages I-IV, diagnosed between 1996 and 2013, and followed up until 2016. DDR2 expression was assessed using immunohistochemistry on tissue microarray slides. The microRNAs were evaluated by qRT-PCR. DDR2 expression was high in 11 (14.1%) women. PFS was significantly lower in women with FIGO stage I/II – versus III/IV, post-surgery residual disease and high expression of DDR2. Women with postsurgery residual disease, FIGO stage I/II – versus III/IV and DDR2 expression had worse OS, but only post-surgery residual disease remained an independent prognostic factor for worse OS in multivariable analysis. miR-182 expression levels were significantly lower in patients harboring tumors with higher expression of DDR2 (p < 0.001). In this relatively large cohort of women with HSGOC, higher DDR2 expression was associated with lower miR-182 levels and worse PFS, suggesting that these molecules may be associated with mechanisms of HGSOC progression.

1 March 2018 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
PDF file
LSLuis Felipe Sallum
Luis Felipe Sallum
LALiliana Andrade
Liliana Andrade
LCLarissa Bastos Eloy da Costa
Larissa Bastos Eloy da Costa
SRSusana Ramalho
Susana Ramalho
AFAmanda Canato Ferracini
Amanda Canato Ferracini
SDSophie Françoise Mauricette Derchain
Sophie Françoise Mauricette Derchain

1 December 2014 in Revista Brasileira de Ginecologia e Obstetrícia
Verified
Journal Article
Open access
PDF file
KSKatia Piton Serra
Katia Piton Serra
SRSusana Ramalho
Susana Ramalho
RTRenato Torresan
Renato Torresan
JVJose Vassallo
Jose Vassallo
LSLuís Otávio Sarian
Luís Otávio Sarian
SDSophie Françoise Mauricette Derchain
Sophie Françoise Mauricette Derchain
Palavras-Chave: Neoplasias da mama; Prognóstico; Receptores estrogênicos